Priya Gomathi Kumaravelu, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 35
- 10 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Good Samaritan Hospital · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
35 plans · 10 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kumaravelu’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
35 of 35 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
| AARP Medicare Advantage from UHC CA-10 (HMO-POS) | UnitedHealthcare | Listed, may be out of date | Jun 10, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$148,479
Medicare paid this office $148,479 for 276 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 63 | $45,413 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 101 | $42,123 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 125 | $21,737 | $154 |
| Return visit (30+ min) | 68 | $13,410 | $121 |
| Short return visit (20+ min) | 87 | $13,270 | $85 |
See all 8 services
| Long return visit (40+ min) | 63 | $45,413 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 101 | $42,123 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 125 | $21,737 | $154 |
| Return visit (30+ min) | 68 | $13,410 | $121 |
| Short return visit (20+ min) | 87 | $13,270 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $4,243 | $74 |
| New patient visit (45+ min) | 29 | $4,223 | $146 |
| New patient visit (60+ min) | 16 | $3,319 | $207 |
Who their Medicare patients are
276 Original Medicare patients in 2024. Average age 77 · Under 65 5% · 85 and older 23% · Women 55% · Also on Medicaid 63% · Health risk score 2.30. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 55% · Chronic kidney disease 41% · Cancer 37% · Coronary heart disease 36% · Heart failure 32% · Atrial fibrillation 29% · Dementia 22% · COPD 20% · Stroke 19% · Depression 16%.
The office billed $417,730, Medicare allowed $193,989 and paid $148,479; for 1,149 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 276 | 1,149 | 77 | 2.30 | $417,730 | $148,479 |
| 2023 | 303 | 1,530 | 76 | 2.21 | $523,050 | $177,702 |
| 2022 | 256 | 1,403 | 75 | 2.29 | $490,879 | $156,280 |
| 2021 | 307 | 1,777 | 75 | 2.48 | $610,070 | $198,331 |
| 2020 | 312 | 1,776 | 75 | 2.66 | $577,352 | $179,496 |
| 2019 | 276 | 1,716 | 75 | 2.95 | $291,660 | $159,878 |
| 2018 | 231 | 1,791 | 74 | 2.75 | $443,743 | $171,575 |
| 2017 | 245 | 1,471 | 74 | 2.70 | $358,196 | $141,739 |
| 2016 | 157 | 536 | 73 | 2.56 | $104,235 | $48,000 |
| 2015 | 44 | 76 | 73 | 1.75 | $19,040 | $6,378 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 135 | $67,034 | $109 |
| Long return visit (40+ min) | 60 | $32,766 | $166 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 171 | $29,327 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 63 | $18,479 | $72 |
| Return visit (30+ min) | 69 | $12,240 | $118 |
| Short return visit (20+ min) | 68 | $8,319 | $78 |
| New patient visit (60+ min) | 21 | $4,418 | $210 |
| New patient visit (45+ min) | 21 | $3,382 | $161 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,364 | $114 |
2022: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 135 | $54,026 | $93 |
| Long return visit (40+ min) | 59 | $39,684 | $161 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 148 | $28,130 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 63 | $12,038 | $64 |
| Return visit (30+ min) | 57 | $8,226 | $103 |
| Short return visit (20+ min) | 59 | $6,088 | $69 |
| New patient visit (60+ min) | 23 | $4,774 | $208 |
| New patient visit (45+ min) | 11 | $1,583 | $144 |
2021: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 190 | $79,494 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 209 | $41,770 | $176 |
| Long return visit (40+ min) | 63 | $36,846 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 83 | $16,260 | $65 |
| Return visit (30+ min) | 68 | $12,379 | $116 |
| Short return visit (20+ min) | 58 | $6,372 | $76 |
| New patient visit (60+ min) | 14 | $2,803 | $200 |
2020: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 170 | $66,916 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 183 | $37,374 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 131 | $29,736 | $65 |
| Long return visit (40+ min) | 43 | $23,280 | $129 |
| Return visit (30+ min) | 61 | $9,611 | $96 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $5,832 | $110 |
| Short return visit (20+ min) | 39 | $3,135 | $58 |
| New patient visit (45+ min) | 13 | $1,944 | $150 |
2019: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 144 | $51,293 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 154 | $30,500 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 136 | $28,748 | $60 |
| Long return visit (40+ min) | 43 | $24,748 | $119 |
| Return visit (30+ min) | 60 | $7,985 | $89 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 57 | $6,328 | $109 |
| Short return visit (20+ min) | 36 | $3,455 | $62 |
| New patient visit (45+ min) | 18 | $2,462 | $137 |
| New patient visit (60+ min) | 14 | $2,299 | $164 |
2018: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 150 | $76,575 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 131 | $27,032 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 110 | $24,429 | $62 |
| Long return visit (40+ min) | 39 | $19,337 | $127 |
| Return visit (30+ min) | 59 | $9,453 | $95 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 73 | $8,434 | $108 |
| New patient visit (45+ min) | 13 | $1,832 | $141 |
| Short return visit (20+ min) | 14 | $1,331 | $67 |
| Advance care planning, first 30 minutes | 16 | $1,247 | $69 |
2017: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 134 | $61,202 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 109 | $27,078 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 109 | $21,999 | $177 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 95 | $12,009 | $118 |
| Long return visit (40+ min) | 26 | $10,088 | $135 |
| Return visit (30+ min) | 29 | $4,053 | $101 |
| New patient visit (45+ min) | 12 | $1,799 | $150 |
2016: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $23,425 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 70 | $11,253 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,850 | $180 |
| Hospital discharge day management, more than 30 minutes | 36 | $3,598 | $97 |
2015: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,053 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,753 | $65 |
Medicaid work
$1,128 in 2024
Medicaid paid $1,128 for 596 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| 1ST HOSP IP/OBS HIGH 75 | 56 | $795 |
| Long return visit (40+ min) | 312 | $172 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 45 | $137 |
| Short return visit (20+ min) | 168 | $24 |
| Return visit (30+ min) | 15 | $0 |
| 2024 | 596 | 5 | 34 | $1,128 |
| 2023 | 829 | 5 | 32 | $4,964 |
| 2022 | 1,225 | 5 | 30 | $8,334 |
| 2021 | 834 | 6 | 25 | $4,657 |
| 2020 | 502 | 3 | 18 | $3,724 |
| 2019 | 406 | 6 | 21 | $3,261 |
| 2018 | 113 | 2 | 14 | $576 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 168 | $1,713 |
| 1ST HOSP IP/OBS HIGH 75 | 100 | $1,456 |
| Long return visit (40+ min) | 377 | $1,428 |
| Return visit (30+ min) | 57 | $213 |
| Short return visit (20+ min) | 127 | $154 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 571 | $4,203 |
| 1ST HOSP IP/OBS HIGH 75 | 161 | $2,067 |
| Long return visit (40+ min) | 362 | $1,701 |
| Short return visit (20+ min) | 86 | $185 |
| Return visit (30+ min) | 45 | $179 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 346 | $1,652 |
| 1ST HOSP IP/OBS HIGH 75 | 117 | $1,463 |
| Long return visit (40+ min) | 274 | $1,425 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 25 | $42 |
| Return visit (30+ min) | 25 | $41 |
| Short return visit (20+ min) | 47 | $34 |
2020
| 1ST HOSP IP/OBS HIGH 75 | 97 | $1,776 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 265 | $1,424 |
| Long return visit (40+ min) | 140 | $524 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 161 | $1,287 |
| 1ST HOSP IP/OBS HIGH 75 | 60 | $973 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 135 | $752 |
| Long return visit (40+ min) | 24 | $126 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 14 | $81 |
| Return visit (30+ min) | 12 | $41 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 101 | $344 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $233 |
Drugs they prescribed that Part D paid
$2,785,702
Pharmacies billed $2,785,702 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (28 of 937) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
647 generic and 290 brand-name prescriptions · $2,785,702 in drug cost · 19 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Imbruvica | 33 | $427,181 | $12,945 |
| Tagrisso | 24 | $380,377 | $15,849 |
| Calquence | 21 | $323,482 | $15,404 |
| Xtandi | 18 | $247,167 | $13,732 |
| Sprycel | 15 | $235,378 | $15,692 |
See all 25 drugs
| Imbruvica | 33 | $427,181 | $12,945 |
| Tagrisso | 24 | $380,377 | $15,849 |
| Calquence | 21 | $323,482 | $15,404 |
| Xtandi | 18 | $247,167 | $13,732 |
| Sprycel | 15 | $235,378 | $15,692 |
| Lynparza | 12 | $219,148 | $18,262 |
| Revlimid | 13 | $196,967 | $15,151 |
| Venclexta | 13 | $175,404 | $13,493 |
| Promacta | 12 | $86,401 | $7,200 |
| Eliquis | 89 | $62,748 | $705 |
| Abiraterone Acetate | 42 | $49,256 | $1,173 |
| Imatinib Mesylate | 19 | $23,051 | $1,213 |
| Xarelto | 21 | $17,199 | $819 |
| Ondansetron Odt | 71 | $2,115 | $30 |
| Letrozole | 88 | $1,288 | $15 |
| Hydroxyurea | 53 | $841 | $16 |
| Anastrozole | 42 | $839 | $20 |
| Tamoxifen Citrate | 28 | $669 | $24 |
| Dexamethasone | 64 | $581 | $9 |
| Tamsulosin | 11 | $460 | $42 |
| Hydrocodone-Acetaminophen | 22 | $353 | $16 |
| Prednisone | 51 | $302 | $6 |
| Duloxetine | 11 | $95 | $9 |
| Azithromycin | 13 | $82 | $6 |
| Raloxifene | 11 | $68 | $6 |
Year by year
| 2024 | 937 | 161 | 3% (28) | 31% | $2,785,702 |
| 2023 | 635 | 135 | 2% (12) | None | $2,408,055 |
| 2022 | 626 | 121 | 3% (16) | 42% | $2,245,924 |
| 2021 | 590 | 92 | 4% (22) | 37% | $1,880,514 |
| 2020 | 365 | 71 | None | 38% | $1,129,877 |
| 2019 | 302 | 61 | None | 41% | $1,116,861 |
| 2018 | 256 | 47 | 5% (13) | 43% | $803,129 |
| 2017 | 103 | 31 | None | 23% | $149,690 |
| 2016 | 42 | 23 | None | None | $55,839 |
| 2015 | 23 | None | None | 61% | $10,425 |
| 2014 | 53 | 21 | None | 43% | $67,598 |
| 2013 | 44 | 11 | 25% (11) | 34% | $10,856 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Imbruvica | 41 | $531,690 | $12,968 |
| Revlimid | 19 | $335,928 | $17,680 |
| Calquence | 13 | $196,108 | $15,085 |
| Venclexta | 12 | $179,807 | $14,984 |
| Eliquis | 97 | $62,751 | $647 |
| Abiraterone Acetate | 12 | $58,687 | $4,891 |
| Imatinib Mesylate | 20 | $43,169 | $2,158 |
| Deferasirox | 11 | $41,818 | $3,802 |
| Letrozole | 46 | $2,597 | $56 |
| Ondansetron Odt | 40 | $1,980 | $49 |
| Bicalutamide | 13 | $1,733 | $133 |
| Hydroxyurea | 37 | $1,649 | $45 |
| Anastrozole | 37 | $1,634 | $44 |
| Tamoxifen Citrate | 26 | $1,437 | $55 |
| Dexamethasone | 23 | $214 | $9 |
| Ondansetron | 11 | $211 | $19 |
| Prednisone | 22 | $177 | $8 |
| Duloxetine | 15 | $160 | $11 |
| Alendronate | 11 | $118 | $11 |
2022: 19 drugs
| Imbruvica | 41 | $569,542 | $13,891 |
| Tagrisso | 26 | $454,392 | $17,477 |
| Revlimid | 21 | $302,872 | $14,422 |
| Venclexta | 12 | $166,337 | $13,861 |
| Xtandi | 11 | $160,879 | $14,625 |
| Eliquis | 96 | $61,317 | $639 |
| Imatinib Mesylate | 15 | $35,125 | $2,342 |
| Retacrit | 12 | $5,627 | $469 |
| Letrozole | 45 | $5,409 | $120 |
| Ondansetron Odt | 50 | $1,859 | $37 |
| Duloxetine | 19 | $1,059 | $56 |
| Tamoxifen Citrate | 22 | $858 | $39 |
| Dexamethasone | 43 | $678 | $16 |
| Hydroxyurea | 21 | $374 | $18 |
| Anastrozole | 16 | $358 | $22 |
| Hydrocodone-Acetaminophen | 16 | $259 | $16 |
| Famotidine | 21 | $181 | $9 |
| Acyclovir | 16 | $156 | $10 |
| Prednisone | 14 | $130 | $9 |
2021: 16 drugs
| Imbruvica | 26 | $391,513 | $15,058 |
| Pomalyst | 19 | $390,568 | $20,556 |
| Revlimid | 30 | $387,588 | $12,920 |
| Venclexta | 11 | $143,813 | $13,074 |
| Eliquis | 71 | $41,462 | $584 |
| Xarelto | 13 | $7,570 | $582 |
| Dexamethasone | 67 | $1,390 | $21 |
| Ondansetron Odt | 34 | $1,256 | $37 |
| Anastrozole | 31 | $885 | $29 |
| Acyclovir | 23 | $484 | $21 |
| Hydroxyurea | 19 | $461 | $24 |
| Letrozole | 41 | $448 | $11 |
| Tamoxifen Citrate | 12 | $419 | $35 |
| Hydrocodone-Acetaminophen | 19 | $302 | $16 |
| Famotidine | 22 | $191 | $9 |
| Alendronate | 13 | $108 | $8 |
2020: 11 drugs
| Pomalyst | 13 | $250,644 | $19,280 |
| Imbruvica | 17 | $225,636 | $13,273 |
| Revlimid | 11 | $190,377 | $17,307 |
| Eliquis | 45 | $26,291 | $584 |
| Ondansetron Odt | 21 | $787 | $37 |
| Anastrozole | 25 | $765 | $31 |
| Dexamethasone | 31 | $628 | $20 |
| Hydroxyurea | 14 | $487 | $35 |
| Prednisone | 17 | $123 | $7 |
| Loperamide | 12 | $106 | $9 |
| Alendronate | 12 | $98 | $8 |
2019: 9 drugs
| Revlimid | 22 | $401,178 | $18,235 |
| Imbruvica | 25 | $317,109 | $12,684 |
| Eliquis | 33 | $16,630 | $504 |
| Xarelto | 11 | $8,843 | $804 |
| Hydroxyurea | 12 | $701 | $58 |
| Anastrozole | 22 | $400 | $18 |
| Dexamethasone | 14 | $325 | $23 |
| Alendronate | 13 | $106 | $8 |
| Acyclovir | 11 | $48 | $4 |
2018: 9 drugs
| Revlimid | 16 | $217,643 | $13,603 |
| Imbruvica | 16 | $195,630 | $12,227 |
| Sprycel | 12 | $157,027 | $13,086 |
| Xarelto | 17 | $8,771 | $516 |
| Eliquis | 15 | $7,799 | $520 |
| Dexamethasone | 22 | $529 | $24 |
| Anastrozole | 23 | $455 | $20 |
| Prednisone | 13 | $127 | $10 |
| Alendronate | 13 | $105 | $8 |
2017: 1 drug
| Anastrozole | 15 | $284 | $19 |
Money from drug and device companies
$2,216 in 2025
| 2025 | 28 | 75 | None | $2,216 |
| 2024 | 27 | 96 | None | $2,232 |
| 2023 | 25 | 75 | None | $1,504 |
| 2022 | 17 | 41 | None | $1,017 |
| 2021 | 17 | 37 | None | $752 |
| 2019 | 6 | 11 | None | $202 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $440 | 9 payments
|
| Janssen Biotech | Rybrevant | $318 | 11 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $209 | 6 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $147 | 1 payment
|
| Aveo Pharmaceuticals | Fotivda | $125 | 2 payments
|
| Novartis Pharmaceuticals | Pluvicto | $108 | 4 payments
|
See all 70 published payments
| Janssen Biotech | Meals · 2025-12-11 | Erleada | $11 |
| Pfizer | Meals · 2025-12-03 | Ibrance | $20 |
| Aveo Pharmaceuticals | Education · 2025-12-02 | Fotivda | $95 |
| Aveo Pharmaceuticals | Meals · 2025-12-02 | Fotivda | $30 |
| Abbvie | Meals · 2025-12-02 | Imbruvica | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-11 | Opdivo | $15 |
| Janssen Biotech | Meals · 2025-11-03 | Erleada | $24 |
| GlaxoSmithKline | Meals · 2025-10-31 | Jemperli | $15 |
| Genentech USA | Meals · 2025-10-30 | Polivy | $22 |
| Novartis Pharmaceuticals | Meals · 2025-10-29 | Pluvicto | $31 |
| Tactile Systems Technology | Meals · 2025-10-20 | Flexitouch Plus | $17 |
| Gilead Sciences | Meals · 2025-10-15 | Trodelvy | $19 |
| GlaxoSmithKline | Meals · 2025-10-14 | Ojjaara | $24 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-10-13 | None | $100 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-07 | Opdivo | $19 |
| Eisai | Meals · 2025-09-30 | Lenvima | $18 |
| PharmaEssentia USA | Meals · 2025-09-24 | Besremi | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-23 | Imfinzi | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-18 | Calquence | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-16 | Tagrisso | $17 |
| Array Biopharma | Meals · 2025-09-10 | Xalkori | $33 |
| Astellas Pharma US | Meals · 2025-08-27 | Xtandi | $24 |
| Novocure | Meals · 2025-08-26 | Optune Lua (Novottf-200t) | $26 |
| Caris MPI | Meals · 2025-08-21 | Mi Cancer Seek | $22 |
| Novartis Pharmaceuticals | Meals · 2025-08-20 | Pluvicto | $25 |
| Janssen Biotech | Meals · 2025-08-19 | Erleada | $16 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-12 | Opdivo | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-30 | Opdivo | $17 |
| Janssen Biotech | Meals · 2025-07-29 | Erleada | $11 |
| PharmaEssentia USA | Meals · 2025-07-29 | Besremi | $28 |
| Abbott Laboratories | Meals · 2025-07-24 | Freestyle Libre 3 | $147 |
| Daiichi Sankyo | Meals · 2025-07-22 | Datroway | $29 |
| Sobi | Meals · 2025-07-22 | Vonjo | $39 |
| Novartis Pharmaceuticals | Meals · 2025-07-17 | Kisqali | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Lynparza | $125 |
| Daiichi Sankyo | Meals · 2025-07-08 | Datroway | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-08 | Calquence | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-27 | None | $32 |
| Pfizer | Meals · 2025-06-25 | Elrexfio | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-19 | Nubeqa | $22 |
| Eisai | Meals · 2025-06-16 | Lenvima | $28 |
| GlaxoSmithKline | Meals · 2025-06-11 | Jemperli | $21 |
| Daiichi Sankyo | Meals · 2025-06-11 | Enhertu | $23 |
| Janssen Biotech | Meals · 2025-06-05 | Rybrevant | $39 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-05 | Opdivo | $124 |
| Array Biopharma | Meals · 2025-06-05 | Xalkori | $25 |
| Abbvie | Meals · 2025-05-29 | Epkinly | $29 |
| Janssen Biotech | Meals · 2025-05-20 | Erleada | $14 |
| Janssen Biotech | Meals · 2025-04-24 | Rybrevant | $117 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-22 | Tagrisso | $24 |
| Pfizer | Meals · 2025-04-17 | Ibrance | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-16 | Nubeqa | $36 |
| Regeneron Healthcare Solutions | Meals · 2025-04-10 | Libtayo | $32 |
| Janssen Biotech | Meals · 2025-04-03 | Carvykti | $20 |
| Janssen Biotech | Meals · 2025-03-26 | Erleada | $11 |
| Novartis Pharmaceuticals | Meals · 2025-03-20 | Kisqali | $31 |
| Astellas Pharma US | Meals · 2025-03-18 | Vyloy | $22 |
| Jazz Pharmaceuticals | Meals · 2025-03-13 | Ziihera | $36 |
| Gilead Sciences | Meals · 2025-03-04 | Trodelvy | $17 |
| Janssen Biotech | Meals · 2025-02-25 | Rybrevant | $31 |
| Coherus Oncology | Meals · 2025-02-13 | Loqtorzi | $26 |
| Sumitomo Pharma America | Meals · 2025-02-11 | Orgovyx | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-10 | Imfinzi | $62 |
| Sirtex Medical | Meals · 2025-02-06 | Sir-Spheres Microspheres | $19 |
| Celgene | Meals · 2025-02-05 | Reblozyl | $20 |
| Array Biopharma | Meals · 2025-01-30 | Xalkori | $14 |
| Deciphera Pharmaceuticals | Meals · 2025-01-29 | Qinlock | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-16 | Opdivo | $15 |
| Janssen Biotech | Meals · 2025-01-15 | Erleada | $22 |
| Celgene | Meals · 2025-01-14 | Reblozyl | $18 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $2,232
| AstraZeneca Pharmaceuticals LP | Imfinzi | $420 | 13 payments
|
| Janssen Biotech | Darzalex | $398 | 16 payments
|
| Pfizer | Ibrance | $237 | 10 payments
|
| Novartis Pharmaceuticals | Pluvicto | $127 | 4 payments
|
| Incyte | Jakafi | $111 | 2 payments
|
| Abbvie | Venclexta | $89 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $88 | 6 payments
|
| GlaxoSmithKline | Jemperli | $80 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $70 | 3 payments
|
| Astellas Pharma US | Padcev | $61 | 3 payments
|
| Sobi | Vonjo | $56 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $53 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $51 | 2 payments
|
| Daiichi Sankyo | Enhertu | $44 | 2 payments
|
| Mirati Therapeutics | Krazati | $43 | 2 payments
|
| Taiho Oncology | Lonsurf | $36 | 2 payments
|
| EMD Serono | None | $35 | 2 payments
|
| Sumitomo Pharma America | Orgovyx | $31 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $28 | 1 payment
|
| Pharmacosmos Therapeutics | Monoferric | $26 | 1 payment
|
| Coherus Biosciences | Udenyca | $26 | 1 payment
|
| Celgene | Reblozyl | $26 | 1 payment
|
| Sirtex Medical | Sir-Spheres Microspheres | $25 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $20 | 1 payment
|
| Lilly USA | Verzenio | $19 | 1 payment
|
| Genzyme | Sarclisa | $16 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $14 | 1 payment
|
2023: $1,504
| AstraZeneca Pharmaceuticals LP | Imfinzi | $211 | 12 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $178 | 14 payments
|
| Lilly USA | Verzenio | $142 | 8 payments
|
| Janssen Biotech | Rybrevant | $136 | 5 payments
|
| Novartis Pharmaceuticals | Tasigna | $124 | 5 payments
|
| Pfizer | Xalkori | $76 | 3 payments
|
| Rigel Pharmaceuticals | Rezlidhia | $62 | 3 payments
|
| Genentech USA | Avastin | $58 | 2 payments
|
| Astellas Pharma US | Padcev | $57 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $55 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $39 | 2 payments
|
| Genzyme | Sarclisa | $37 | 2 payments
|
| Myriad Genetic Laboratories | Precisetumor | $37 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $33 | 1 payment
|
| Sobi | Doptelet | $32 | 1 payment
|
| Pharmacosmos Therapeutics | Monoferric | $27 | 1 payment
|
| Daiichi Sankyo | Enhertu | $26 | 1 payment
|
| Celgene | Reblozyl | $24 | 1 payment
|
| Incyte | Pemazyre | $24 | 1 payment
|
| Eisai | Lenvima | $23 | 1 payment
|
| Amgen | Nplate | $23 | 1 payment
|
| ADC Therapeutics America | None | $22 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Epkinly | $20 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $20 | 1 payment
|
| CTI BioPharma | Vonjo | $18 | 1 payment
|
2022: $1,017
| AstraZeneca Pharmaceuticals LP | Calquence | $184 | 7 payments
|
| Janssen Biotech | Imbruvica | $161 | 4 payments
|
| Novartis Pharmaceuticals | Kisqali | $108 | 5 payments
|
| Lilly USA | Verzenio | $104 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $92 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $75 | 3 payments
|
| Abbvie | Venclexta | $52 | 2 payments
|
| Eisai | Lenvima | $48 | 2 payments
|
| GlaxoSmithKline | Blenrep | $29 | 1 payment
|
| Puma Biotechnology | Nerlynx | $28 | 1 payment
|
| BTG International | Voraxaze | $25 | 1 payment
|
| Seagen | Padcev | $25 | 1 payment
|
| Amgen | Nplate | $23 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $19 | 1 payment
|
| Celgene | Reblozyl | $18 | 1 payment
|
| Genentech USA | Alecensa | $14 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $12 | 1 payment
|
2021: $752
| Lilly USA | Cyramza | $98 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $86 | 4 payments
|
| Eisai | Lenvima | $80 | 4 payments
|
| Pfizer | Inlyta | $75 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $70 | 3 payments
|
| Janssen Biotech | Erleada | $69 | 3 payments
|
| Array Biopharma | Braftovi | $43 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $35 | 2 payments
|
| Celgene | Abecma | $31 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $30 | 2 payments
|
| BTG International | Voraxaze | $22 | 1 payment
|
| Astellas Pharma US | Padcev | $21 | 1 payment
|
| Kite Pharma | None | $20 | 1 payment
|
| Seagen | Padcev | $19 | 1 payment
|
| Daiichi Sankyo | Enhertu | $19 | 1 payment
|
| GlaxoSmithKline | Blenrep | $18 | 1 payment
|
| Aveo Pharmaceuticals | Fotivda | $17 | 1 payment
|
2019: $202
| AstraZeneca Pharmaceuticals LP | Tagrisso | $93 | 4 payments
|
| Janssen Biotech | Darzalex | $33 | 2 payments
|
| Eisai | Lenvima | $32 | 2 payments
|
| Pfizer | Ibrance | $18 | 1 payment
|
| Gilead Sciences | None | $15 | 1 payment
|
| Terumo Medical | Tr Band | $12 | 1 payment
|
Checkups this office reported
5 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 100%That's most of the people this applied to. | 795 |
| Breast cancer screeningEligible women who got a mammogram | 100%That's most of the people this applied to. | 505 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 100%That's most of the people this applied to. | 960 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 3,030 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 100%That's most of the people this applied to. | 955 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
Professional record
- NPI
- 1154514677
- Licence
- MI 4301086299
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 2589 Samaritan Dr, San Jose, CA, 95124
- NPI first listed
- 2007-08-20
- NPI last updated
- 2026-04-01
- NPI record certified
- 2026-04-01
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 175 N Jackson Ave, San Jose, CA, 95116